TransMedics Group, Inc. (TMDX) Q2 2026 Earnings Call Transcript

SA Transcripts 161.49K Followers Follow TransMedics Group, Inc. ( TMDX ) Q2 2026 Earnings Call August 4, 2026 4:30 PM EDT Company Participants Waleed Hassanein - Founder, President, CEO & Director Gerardo Hernandez - CFO & Treasurer Conference Call Participants Hannah Jeffrey - The Gilmartin Group K. Gong - JPMorgan Chase & Co, Research Division Joshua Jennings - TD Cowen, Research Division William Plovanic - Canaccord Genuity Corp., Research Division Matthew Mardula - William Blair & Company L.L.C., Research Division Samantha Munoz - Piper Sandler & Co., Research Division Patrick Wood Daniel Markowitz - Evercore ISI Institutional Equities, Research Division Young Li - Jefferies LLC, Research Division Suraj Kalia - Oppenheimer & Co. Inc., Research Division Michael Matson - Needham & Company, LLC, Research Division David Rescott - Robert W. Baird & Co. Incorporated, Research Division Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Good afternoon, and welcome to TransMedics Second Quarter 2026 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Hannah Jeffrey from The Gilmartin Group for a few introductory comments. Hannah Jeffrey The Gilmartin Group Thank you. Earlier today, TransMedics released financial results for the quarter ended June 30, 2026. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call, including during the question-and-answer portion of the call, that include forward-looking statements within the meaning of federal securities laws. Any statements made during this call that can relate to future events, results or performance, including expectations or predictions, are forward-looking statements. All forward-looking statements, including, without limitation, our examination of operating trends, the potential commercial opportunity for our products and services, the potential timing, benefits or outcomes of new clinical programs and our future financial expectations, which include expectations for growth in our organization and guidance and/or expectations for revenue, gross